To thoroughly carry out the Implementation Plan for Construction of Suzhou Bio-pharmaceutical Industry Innovation Cluster, facilitate the application and promotion of local innovative drugs and devices in the region, on July 7, the hospital and enterprise docking activity for innovative, famous, and high-quality product of Suzhou bio-pharmaceutical industry jointly hosted by Suzhou Industry and Information Technology Bureau, Suzhou Municipal Health Commission and Suzhou Municipal Medical Insurance Bureau was successfully held.

Hospital representatives that attended the meeting:

Suzhou Municipal Hospital

The First Affiliated Hospital of Soochow University

The Second Affiliated Hospital of Soochow University

Enterprise representatives that attended the meeting:

Innovent Biologics (Suzhou) Co., Ltd.

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Baiji Shenzhou (Suzhou) Biotechnology Co., Ltd.

Zengding Pharmaceutical (Suzhou) Co., Ltd.

Peijia Medical (Suzhou) Co., Ltd.

Huqiu Imaging (Suzhou) Co., Ltd.

At the meeting, government authorities, medical institutions and key enterprises conducted a discussion about how to properly utilize the “Marketing Application Mechanism for Innovative, Famous, and High-quality Suzhou Bio-pharmaceutical Products”.

Representatives from medical institutions said they would actively procure innovative, famous, and high-quality products, render full support to promote and use local innovative products in the hospital, meanwhile, they also encouraged enterprises to conduct clinical trials in local hospitals to benefit local patients and improve the clinical capacity of the local hospitals. Representatives from key enterprises said that as new products being approved in succession, they hoped that the products might be used in local hospitals as soon as possible, and expected to strengthen cooperation with local medical institutions through the platform constructed by the government. Topics such as implementation of corresponding supportive policies were also discussed at the meeting.

As special commodities, drugs and medical devices have the characteristic that shall be consumed under the direction of doctors, and most of the sales happens in medical institutions, accelerate the “last mile” of entering hospital is the common appeal of drug and medical device manufactures. With the coming of innovative achievement conversion period of Suzhou bio-pharmaceutical industry, various innovative drugs, high-value consumables, high-end medical devices will go on the market in succession, to facilitate the local market expansion for local innovative products, Suzhou has implemented a series of measures:

In April 2021, established the Marketing Application Mechanism for Innovative, Famous, and High-quality Suzhou Bio-pharmaceutical Products to support Suzhou drugs, Suzhou medical devices and Suzhou consumables.

In November 2021, established the first batch of  Catalog of Innovative, Famous, and High-quality Products of Suzhou Bio-pharmaceutical and Health Industry for Promotion and Application, and issued to major medical institutions in Suzhou, and 18 key enterprises and 25 products were shortlisted.

In March 2022, provided support to procurement of enterprises and public institutions.

In June 2022, guided and supported local medical institutions to procure and apply, which would not be included into the assessment scope of drug ratio and consumables ratio of the medical institution.

In the second half, Suzhou will conduct the certification for the second batch of the Catalog of Innovative, Famous, and High-quality Products of Suzhou Bio-pharmaceutical and Health Industry for Promotion and Application

--Sourced from WeChat official account of the Bureau of Industry and Information Technology of Suzhou